ROMANIELLO, DONATELLA
 Distribuzione geografica
Continente #
AS - Asia 1.831
EU - Europa 1.313
NA - Nord America 1.193
SA - Sud America 159
AF - Africa 47
OC - Oceania 2
Totale 4.545
Nazione #
US - Stati Uniti d'America 1.176
IT - Italia 707
SG - Singapore 652
CN - Cina 526
VN - Vietnam 315
HK - Hong Kong 141
DE - Germania 138
BR - Brasile 130
IE - Irlanda 88
KR - Corea 83
GB - Regno Unito 68
NL - Olanda 59
SE - Svezia 58
RU - Federazione Russa 40
FI - Finlandia 34
AT - Austria 29
IN - India 26
FR - Francia 25
CI - Costa d'Avorio 21
ID - Indonesia 20
JP - Giappone 19
AR - Argentina 17
ES - Italia 17
BG - Bulgaria 12
CH - Svizzera 10
SC - Seychelles 10
CA - Canada 9
JO - Giordania 9
DK - Danimarca 8
TG - Togo 8
BD - Bangladesh 7
PL - Polonia 7
EC - Ecuador 6
IR - Iran 6
MX - Messico 6
BE - Belgio 5
TR - Turchia 5
ZA - Sudafrica 5
PK - Pakistan 4
MY - Malesia 3
PY - Paraguay 3
AZ - Azerbaigian 2
IL - Israele 2
NP - Nepal 2
NZ - Nuova Zelanda 2
RO - Romania 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
DZ - Algeria 1
GR - Grecia 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
ML - Mali 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
TJ - Tagikistan 1
UA - Ucraina 1
Totale 4.545
Città #
Singapore 405
Bologna 355
Hefei 196
Ashburn 152
Hong Kong 140
Santa Clara 125
Chandler 112
Ho Chi Minh City 93
Hanoi 92
Dublin 85
Seoul 81
Princeton 70
Beijing 69
Boardman 56
Dallas 51
Milan 42
Berlin 37
Southend 36
Los Angeles 35
Fairfield 32
Modena 30
Munich 28
Medford 22
Vienna 22
Abidjan 21
Buffalo 21
Rome 21
Seattle 20
Guangzhou 18
Helsinki 18
London 18
Amsterdam 17
Bengaluru 17
Redondo Beach 17
São Paulo 17
New York 16
Nuremberg 16
Brescia 13
Frankfurt am Main 13
Jakarta 13
Tokyo 13
Da Nang 12
Sofia 12
Ninh Bình 11
Shanghai 11
Lappeenranta 10
Woodbridge 10
Amman 9
Bern 9
Bremen 9
Naples 9
Olalla 9
Chicago 8
Düsseldorf 8
Jinan 8
Lomé 8
Marcon 8
Reggio Emilia 8
San Diego 8
Vũng Tàu 8
Boydton 7
Cambridge 7
Falkenstein 7
Florence 7
Forlì 7
Orem 7
Redmond 7
Stanford 7
Wilmington 7
Brooklyn 6
Bắc Giang 6
Can Tho 6
Turku 6
Alicante 5
Ferrara 5
Houston 5
Hải Dương 5
Phoenix 5
The Dalles 5
Thu Dau Mot 5
Thái Nguyên 5
Tongling 5
Turin 5
Warsaw 5
Xi'an 5
Ann Arbor 4
Bronshoj 4
Brussels 4
Carpi 4
Castel Maggiore 4
Council Bluffs 4
Formigine 4
Ha Long 4
Haiphong 4
Madrid 4
Markaz 4
North Bergen 4
Padova 4
Tianjin 4
Toronto 4
Totale 3.037
Nome #
BMP7 promotes cardiomyocyte regeneration in zebrafish and adult mice 249
The natural sesquiterpene β- caryophyllene acts as an enviromental decontaminant through the interference with the STAT3 signalling pathway 232
Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression 199
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy 187
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib 173
Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation 171
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 169
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies 168
CEA Cell Adhesion Molecule 6 (CEACAM6), Collagen Type I Alpha 2 Chain (COL1A2), Galectin 4 (LGALS4) and Tetraspanin 8 (TSPAN8) mRNAs as blood biomarkers for colorectal cancer 168
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization 167
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies 166
NF-kB oscillation profiles decode response to anti-EGFR monoclonal antibodies 156
PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems 146
NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells 130
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma 113
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 109
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab 96
IL-1 Associated Post Senescence Reprogramming Impairs Response To EGFR Neutralization 95
β-Caryophyllene Counteracts Chemoresistance Induced by Cigarette Smoke in Triple-Negative Breast Cancer MDA-MB-468 Cells 94
Senescence-associated reprogramming impairs response to EGFR neutralization 87
Targeting anaplastic lymphoma kinase in consensus molecular subtype 1 colon cancer patients 69
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 67
JAK2-Regulation Of HER2 “Addiction” In HER2-Positive Breast Cancer Cell Lines 62
Cancer Immunotherapy: The Dawn of Antibody Cocktails 61
First-line therapy based on kinase inhibitors and antibodies prevents resistance in egfr-mutated lung cancer. 61
β-Hexachlorocyclohexane Drives Carcinogenesis in the Human Normal Bronchial Epithelium Cell Line BEAS-2B 58
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor 58
Comparative analysis of the interaction between different flavonoids and pdia3 57
Synergy Between Kinase Inhibitors And Antibodies Enables Upfront Prevention Of Recurring Secondary Resistance In Egfr-Mutated Lung Cancer 56
Biochemical characterization of the ERp57-STAT3 complex 56
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors 54
Senescence-associated reprogramming impairs response to EGFR neutralization 52
Dangerous liaison: organochlorine substances, energy metabolism and cancer 49
Acetylation and phosphorylation of STAT3 are involved in the responsiveness of microglia to beta amyloid 49
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models 48
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer 48
Analysis of stat3 post-translational modifications (ptms) in human prostate cancer with different gleason scores 47
Functional Studies Of Stat3 And Its Interactors In Breast Cancer 47
null 46
STAT3--ERp57 Interplay in human prostate cancer 42
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways 42
STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells 42
Interaction between flavonoids and PDIA3 42
Protease, an Advance Therapeutic Target in Cancer 39
null 39
PARP-1 as coactivator of STAT3 in M14 melanoma cell line 39
STAT3/ERP57/TPX2 axis and process of “androgen escape” in prostate cancer 38
EGFR/STAT3/ERp57 Interplay in human prostate cancer progression 37
STAT3-EGFR PATHWAY IN NEUROENDOCRINE PROSTATE CANCER: A CASE REPORT 34
CIRCADIAN DEPENDENT MOTILITY: THE ROLE FOR THE PERINUCLEAR ACTIN CAP 31
STAT3's role in microglial cells 30
Developing Comprehensive In Vitro and In Vivo Models: Patient-Derived Organoids (PDOs) and Xenografts (PDXs) for Morphological and Functional Analysis and Drug Screening in Head and Neck Squamous Cell Carcinoma 27
Development of Head and Neck Squamous Cell Carcinoma Patient-Derived Xenografts (PDXs) and Organoids (PDXOs) for Morphological Analysis and Drug Screening 25
IL-1 in the microenvironment impairs response to EGFR- neutralization in CRC patients 21
Circadian dependent motility: the role for the perinuclear actin cap 15
IL-1 in the microenvironment impairs response to EGFR- neutralization in CRC patients 11
The ERBB Family of Receptor Tyrosine Kinases: Key Players in Cancer 9
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies 5
null 4
Totale 4.692
Categoria #
all - tutte 15.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.300


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 3 6 1 4 3 1 4
2021/2022294 0 3 0 0 3 3 1 35 42 15 118 74
2022/2023624 53 58 24 55 70 50 16 59 124 10 54 51
2023/2024366 44 42 36 30 22 63 14 27 14 28 16 30
2024/20251.514 33 181 131 94 207 93 171 72 72 113 114 233
2025/20261.794 411 362 299 235 282 205 0 0 0 0 0 0
Totale 4.692